A case report. Osteogenesis imperfecta type III in an adult woman. Ten years of treatment with bisphosphonates. What now?

Authors

  • Carmen Pérez-Blanco Hospital Universitario de Getafe, Getafe (Madrid), Spain
  • Isabel Pavón-de Paz Hospital Universitario de Getafe, Getafe (Madrid), Spain
  • Cristina Navea-Aguilera Hospital Universitario de Getafe, Getafe (Madrid), Spain
  • José Antonio Rosado-Sierra Hospital Universitario de Getafe, Getafe (Madrid), Spain
  • Diego García-García Hospital Universitario de Getafe, Getafe (Madrid), Spain

DOI:

https://doi.org/10.32818/reccmi.a2n2a6

Keywords:

osteogenesis imperfecta, type III, bisphosphonates, zoledronic acid

Abstract

The osteogenesis imperfecta (OI) is a hereditary disease that groups connective tissue disorders, which later cause fragility and bone deformities. Low bone mineral density and high incidence of bone pain and fractures require the application of antiresorptive targeted treatment, where bisphosphonates are the best treatment. We report the case of a 35-year-old female with type III OI who had been treated for ten years with intravenous zoledronic acid. This case allows for the revising of the treatments used to date.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016 Apr; 387(10028): 1657-71.

Sinikimpu JJ, Ojaniemi M, Lehenkari P, et al. Severe osteogenesis imperfecta Type-III and its challenging treatment in newborn and preschool children. A systematic review. Injury. 2015 Aug; 46(8): 1440-6.

Cheung MS, Glorieux FH. Osteogenesis Imperfecta: update on presentation and management. Rev Endocr Metab Disord. 2008 Jun; 9(2): 153-60.

Golshani KR, Ludwig MR, Cohn PL, et al. Osteogenesis Imperfecta. Del Med J. 2016 Jun; 88(6): 178-85.

Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003; 18: 126.

Shapiro JR, Thompson CB, Wu Y, et al. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int. 2010; 87: 120.

Xu XJ, Ma DD, Lv F, et al. The clinical characteristics and efficacy of biphosphonates in adult patients with osteogenesis imperfecta. Endocr Pract 2016 Aug 2.

Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014 Feb; 124(2): 491-8.

Published

2017-08-31

How to Cite

1.
Pérez-Blanco C, Pavón-de Paz I, Navea-Aguilera C, Rosado-Sierra JA, García-García D. A case report. Osteogenesis imperfecta type III in an adult woman. Ten years of treatment with bisphosphonates. What now?. Rev Esp Casos Clin Med Intern [Internet]. 2017 Aug. 31 [cited 2024 Dec. 26];2(2):78-9. Available from: https://www.reccmi.com/RECCMI/article/view/152

Most read articles by the same author(s)